We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Immune Cell Biomarker Predicts Response to Treatment with Checkpoint Inhibitor Drugs

By LabMedica International staff writers
Posted on 06 Sep 2021
Print article
Image: Scanning electron micrograph of a human T-cell from the immune system of a healthy donor (Photo courtesy [U.S.] National Institute of Allergy and Infectious Diseases)
Image: Scanning electron micrograph of a human T-cell from the immune system of a healthy donor (Photo courtesy [U.S.] National Institute of Allergy and Infectious Diseases)
A molecular signature based on an immune cell surface protein is a potential route toward determining a cancer patient’s response to treatment with checkpoint inhibitor drugs.

Immune checkpoint inhibitors are drugs that can aid the immune system of some cancer patients to effectively attack their tumors, but identifying those patients for whom they will be effective is still a challenge.

In this regard, investigators at Memorial Sloan Kettering Cancer Center (New York, NY, USA) designed a study to identify blood-based biomarkers linked to the clinical outcome of immune checkpoint blockade (ICB)-treated patients. For this study, they performed immune profiling of 188 ICB-treated patients with melanoma using multiparametric flow cytometry to characterize immune cells in pretreatment peripheral blood. An independent cohort of 94 ICB-treated patients with urothelial carcinoma was used for validation.

The results revealed three distinct immune phenotypes (immunotypes), defined in part by the presence of a LAG-3+CD8+ T-cell population. LAG-3 (lymphocyte-activation gene 3) is a cell surface protein with diverse biologic effects on T-cell function, including an inhibitory effect on immune responses. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.

Patients with melanoma with a positive LAG immunotype had poorer outcomes after ICB with a median survival of 22.2 months compared to 75.8 months for those with the LAG negative immunotype. An independent cohort of 94 ICB-treated patients with urothelial carcinoma was used for validation where a LAG positive immunotype was significantly associated with response, survival, and progression-free survival.

"If I told you that you could have a simple blood draw and in a couple of days have information to make a decision about what therapy you get, I would say it does not get much better than that," said senior author Dr. Margaret K. Callahan, researcher in medical oncology at Memorial Sloan Kettering Cancer Center. "Of course, there is still much work to be done before these research findings can be applied to patients in the clinic, but we are really enthusiastic about the potential to apply these findings. What I am most excited about is prospectively evaluating the idea that not only can we identify patients who will not do as well with the traditional therapies but that we can also give these patients other treatments that might help them, based on our knowledge of what LAG-3 is doing biologically."

The LAG-3 study was published in the August 25, 2021, online edition of the journal Science Translational Medicine.

Related Links:
Memorial Sloan Kettering Cancer Center

Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
Single Channel Pipette
AHN pipet4u pro
Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
Giardia, Cryptosporidium and E. Histolytica Antigen Test

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.